论文部分内容阅读
赖诺普利(Lisinopril)是一种新型的非巯基类血管紧张素转换酶(ACE)抑制剂,临床疗效优于卡托普利(巯甲丙脯酸)。药物动力学:健康志愿者口服该药后6～8h 达血浆峰值,生物利用度为25±4%。与卡托普利不同,该药的生物利用度不受食物存在或其他降压药的影响。终端t 1/2为
Lisinopril is a novel non-sulfhydryl angiotensin converting enzyme (ACE) inhibitor with superior clinical efficacy over captopril (captopril). Pharmacokinetics: healthy volunteers after oral administration of the drug up to 6 ~ 8h plasma peak bioavailability of 25 ± 4%. Unlike captopril, its bioavailability is independent of food or other antihypertensive drugs. Terminal t 1/2 is